On September 8, INSILICO rose 5.64% in regular trading, trading at HK$51.45 per share, with turnover of HK$72.39 million.

On the news front, INSILICO announced on September 7 a strategic partnership with MobiDrop to co-build AI-Ready multi-omics data infrastructure. Under the agreement, MobiDrop's scaled multi-omics data will be systematically integrated into INSILICO's Pharma.AI platform data warehouse, providing training, validation, and model iteration support for its core generative biology platform PandaOmics and the newly released multi-agent-driven Virtual Aging Cell (VAC) platform.

Multiple recent catalysts have also supported sentiment. The company's chairman disclosed a plan to purchase up to HK$16 million in shares during September using personal funds, signaling confidence in the company's long-term value. Additionally, the company completed a $305 million zero-coupon convertible bond issuance on September 3, with net proceeds of approximately $301.6 million earmarked for clinical trials, R&D team expansion, and scientific foundation models. Citi maintained its Buy rating with an HK$85 target price, naming INSILICO its top sector pick.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)